Previous 10 | Next 10 |
Gainers: BIMI International Medical (NASDAQ:BIMI) +55%. Kezar Life Sciences (NASDAQ:KZR) +31%. CNS Pharmaceuticals (NASDAQ:CNSP) +28%. ReTo Eco-Solutions (NASDAQ:RETO) +28%. Progenity (NASDAQ:PROG) +27%. PLBY Group (NASDAQ:PLBY) +27%. IonQ (NYSE:IONQ) +25%. Kuke (NYSE:KUKE) +21%. On Holding (...
Landos Biopharma, Inc. (LABP) Q3 2021 Earnings Conference Call November 15, 2021 8:00 A.M. ET Company Participants Becky Mosig - Director of Administration and Operations Chris Garabedian - Chairman of the Board Tim Mayleben - Interim President and Chief Executive Officer Conference Call Part...
Landos Biopharma (NASDAQ:LABP): Q3 GAAP EPS of -$0.32 beats by $0.11. Cash and equivalents of $102.7M Press Release For further details see: Landos Biopharma EPS beats by $0.11
Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization Refining Ulcerative Colitis Clinical Development Plans for Omilancor to Generate Additional Phase 2b Data Prior to Initiating Pivotal Phase 3 Program Determining Optimal En...
BLACKSBURG, Va., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma Inc. (NASDAQ: LABP) today announced that it will report third quarter 2021 financial results and host a conference call to provide a corporate update on November 15, 2021. Following the release of the financial result...
A clinical-stage biopharmaceutical company, Landos Biopharma (NASDAQ:LABP) announces that Josep Bassaganya-Riera, Ph.D., has stepped down as Chairman, President and CEO, effective immediately. Tim M. Mayleben, a member of the Board, has been appointed Interim President and CEO. Chris Gar...
Josep Bassaganya-Riera Steps Down as Chairman, President and CEO Tim M. Mayleben Appointed Interim President and CEO Chris Garabedian Appointed Chairman of the Board BLACKSBURG, Va., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma Inc. (NASDAQ: LABP), a clinical-s...
Landos Biopharma (NASDAQ:LABP) announces that the U.S. FDA has cleared the company’s Investigational New Drug (IND) application for LABP-104, a novel, oral, systemically delivered LANCL2 agonist, for the treatment of rheumatoid arthritis (RA). Landos has initiated a Phase 1 trial of LA...
Phase 1 trial is underway with topline results expected in the first half of 2022 Represents Landos’ seventh IND cleared overall and the second IND cleared for LABP-104, a potentially first-in-class therapeutic candidate for systemic lupus erythematosus and rheumatoid art...
Landos Biopharma (NASDAQ:LABP) has dosed the first subject in a Phase 1 study of LABP-104, a potentially first-in-class oral, small-molecule LANCL2 agonist, for the treatment of systemic lupus erythematosus. Systemic lupus erythematosus (SLE) is the most common type of the autoimmune dis...
News, Short Squeeze, Breakout and More Instantly...
Landos Biopharma Inc. Company Name:
LABP Stock Symbol:
NASDAQ Market:
Landos Biopharma Inc. Website:
2024-05-26 06:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
AbbVie Completes Acquisition of Landos Biopharma PR Newswire - Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD) NORTH CHICAGO, Ill....
2024-05-06 13:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...